Onset of Action of Selected Second-Generation Antipsychotics (Pines)-A Systematic Review and Meta-Analyses

被引:2
作者
Meyer, Rikke [1 ]
Skov, Kenneth [1 ,2 ]
Dhillon, Inderjeet Kaur [3 ]
Olsson, Emilie [1 ]
Graudal, Niels Albert [4 ]
Baandrup, Lone [2 ,5 ]
Juergens, Gesche [1 ,2 ]
机构
[1] Zealand Univ Hosp, Clin Pharmacol Unit, Sygehusvej 10, DK-4000 Roskilde, Denmark
[2] Univ Copenhagen, Dept Clin Med, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark
[3] Mental Hlth Serv West, Psychiat Reg Zealand, DK-4200 Slagelse, Denmark
[4] Copenhagen Univ Hosp, Lupus & Vasculitis Clin VRR4242, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
[5] Mental Hlth Ctr Copenhagen, Gentofte Hospitalsvej 15, DK-2900 Copenhagen, Denmark
关键词
antipsychotic action; antipsychotic effect; antipsychotic agents; pines; psychopharmacology; schizophrenia; systematic review; meta-analysis; PALIPERIDONE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ACUTE EXACERBATION; ACUTE SCHIZOPHRENIA; QUETIAPINE FUMARATE; TREATMENT RESPONSE; NEGATIVE SYMPTOMS; EFFICACY; OLANZAPINE;
D O I
10.3390/biomedicines11010082
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recommendations for duration of treatment with antipsychotics before considering a switch vary from 2 to 8 weeks, although several studies suggest a rapid onset of action. The objective of this review was to estimate time to onset of action and time to maximum antipsychotic effect of asenapine, olanzapine, quetiapine, and zotepine (pines). We searched bibliographic databases for randomized, placebo-controlled trials in adults with schizophrenia estimating the antipsychotic effect of pines over time. Thirty-five studies including 6331 patients diagnosed with chronic schizophrenia were included. We estimated the standardized mean differences (SMD) of changes in symptom score from baseline to follow-up between intervention and placebo groups across studies using meta-analysis techniques. The summarized effect across all included pines administered as immediate-release formulations showed a statistically significant effect at week 1 (SMD, -0.20 [CI95% -0.28, -0.13]), which increased until week 3 (SMD, -0.42 [CI95% -0.50, -0.34]), after which the effect leveled off (week 6: SMD, -0.53 [CI95% -0.62, -0.44]). The sensitivity analyses of the individual pines confirm this finding, although data sparsity increases variability and limits conclusiveness of these analyses.
引用
收藏
页数:16
相关论文
共 65 条
  • [1] Delayed-onset hypothesis of antipsychotic action - A hypothesis tested and rejected
    Agid, O
    Kapur, S
    Arenovich, T
    Zipursky, RB
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (12) : 1228 - 1235
  • [2] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
    Arvanitis, LA
    Miller, BG
    Borison, RL
    Pitts, WM
    Sharif, ZA
    Hamner, MB
    Herz, MI
    True, JE
    Velligan, D
    Knesevich, MA
    Small, J
    Steinbook, R
    Hertzman, M
    Keck, PE
    Newcomer, JW
    Grace, J
    Rotrosen, J
    Tandon, R
    Dott, SG
    Ferguson, JM
    Addington, DEN
    MacEwan, GW
    Nair, VNP
    Shriqui, CL
    Williams, R
    Daniel, DG
    Shehi, GM
    Patterson, WM
    Merideth, CH
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (04) : 233 - 246
  • [3] Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
    Barnes, Thomas R. E.
    Drake, Richard
    Paton, Carol
    Cooper, Stephen J.
    Deakin, Bill
    Ferrier, I. Nicol
    Gregory, Catherine J.
    Haddad, Peter M.
    Howes, Oliver D.
    Jones, Ian
    Joyce, Eileen M.
    Lewis, Shon
    Lingford-Hughes, Anne
    MacCabe, James H.
    Owensm, David Cunningham
    Patel, Maxine X.
    Sinclair, Julia M. A.
    Stone, James M.
    Talbot, Peter S.
    Upthegrove, Rachel
    Wieck, Angelika
    Yung, Alison R.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (01) : 3 - 78
  • [4] Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
    Beasley, CM
    Sanger, T
    Satterlee, W
    Tollefson, G
    Tran, P
    Hamilton, S
    Green, A
    Dott, S
    Pfister, G
    Roxas, L
    Small, J
    Thomas, M
    Ames, D
    Schooler, N
    Baker, R
    Levine, R
    Fabre, L
    Friedel, R
    Safferman, A
    Lieberman, J
    Stahl, S
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 159 - 167
  • [5] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial
    Beasley, CM
    Tollefson, G
    Tran, P
    Satterlee, W
    Sanger, T
    Hamilton, S
    Fabre, L
    Small, J
    Ereshefsky, L
    True, J
    Nemeroff, C
    Risch, SC
    Perry, PJ
    Potkin, SG
    Borison, RL
    James, S
    Meltzer, HY
    Iqbal, N
    Fann, WE
    Gewirtz, GR
    Landbloom, R
    RoyByrne, PP
    Tuason, VB
    Carman, JS
    Stokes, PE
    Williams, R
    Ancill, RJ
    MacEwan, GW
    Gujavarty, KS
    Jones, B
    Lohr, JB
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 111 - 123
  • [6] ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
    Borison, RL
    Arvanitis, LA
    Miller, BG
    Alphs, LD
    Carman, JS
    Diamond, B
    Gewirtz, G
    Hamner, MB
    Hirshfield, R
    McEvoy, JP
    Mukherjee, S
    Nasrallah, HA
    Oxenkrug, G
    Ryan, W
    Smith, N
    Tamminga, C
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) : 158 - 169
  • [7] A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - Results from the CandleLyte study
    Bugarski-Kirola, D.
    Wang, A.
    Abi-Saab, D.
    Blaettler, T.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (07) : 1024 - 1036
  • [8] Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia
    Canuso, Carla M.
    Dirks, Bryan
    Carothers, Jennifer
    Kosik-Gonzalez, Colette
    Bossie, Cynthia A.
    Zhu, Young
    Damaraju, C. V.
    Kalali, Amir H.
    Mahmoud, Ramy
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (06) : 691 - 701
  • [9] Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study
    Citrome, Leslie
    Walling, David P.
    Zeni, Courtney M.
    Starling, Brittney R.
    Terahara, Takaaki
    Kuriki, Masaaki
    Park, Alexandra S.
    Komaroff, Marina
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (01)
  • [10] Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
    Cooper, SJ
    Butler, A
    Tweed, J
    Welch, C
    Raniwalla, J
    [J]. PSYCHOPHARMACOLOGY, 2000, 150 (03) : 237 - 243